Decreased deoxycytidine kinase (dCK) has been shown to inhibit PC cell growth and metastasis and sensitize PC cells to gemcitabine treatment by down-regulating the Nrf2 transcriptional activity and decreasing the expression of ARE-driven antioxidant genes [50]. The gene discussed is DCK; the disease is pachyonychia congenita.